Switch from intravenous anti-CD20 therapy to subcutaneous ofatumumab in patients with relapsing MS: results from the OLIKOS study.

ABSTRACT:

Background

Multiple sclerosis (MS) is a chronic condition, and as such, switching therapies is not uncommon. However, data on switching from intravenous (IV) to subcutaneous (SC) formulations of anti-CD20 therapies are lacking.

Methods

OLIKOS, a phase 3b, prospective, single-arm, multicenter study conducted from 2020 to 2024, evaluated the efficacy and safety of switching to SC ofatumumab from IV ocrelizumab or rituximab in adults with relapsing MS. Participants were excluded if they had discontinued anti-CD20 therapy due to suboptimal response or safety concerns. Maintenance of efficacy was defined as either no change or a reduction from baseline in the number of gadolinium-enhancing (Gd +) T1 lesions observed by magnetic resonance imaging (MRI) after 12 months of ofatumuma

SUBMITTER: Hua LH 

PROVIDER: S-EPMC12592291 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature